Journal of Gastroenterology,
Journal Year:
2023,
Volume and Issue:
58(10), P. 947 - 964
Published: July 20, 2023
Hepatocellular
carcinoma
has
a
substantial
global
mortality
burden
which
is
rising
despite
advancements
in
tackling
the
traditional
viral
risk
factors.
Metabolic
(dysfunction)
associated
fatty
liver
disease
(MAFLD)
most
prevalent
disease,
increasing
parallel
with
epidemics
of
obesity,
diabetes
and
systemic
metabolic
dysregulation.
MAFLD
major
factor
behind
this
sustained
rise
HCC
incidence,
both
as
single
entity
often
via
synergistic
interactions
other
diseases.
Mechanisms
MAFLD-related
are
complex
but
crucially
underpinned
by
dysregulation
variable
contributions
from
interacting
modifiers
related
to
environment,
genetics,
dysbiosis
immune
distinct
clinical
presentation,
notably
its
common
occurrence
non-cirrhotic
disease.
This
just
one
several
challenges
effective
surveillance
programmes.
The
response
immune-checkpoint
therapy
currently
controversial,
further
complicated
high
prevalence
individuals
aetiologies.
In
review,
we
highlight
current
data
on
epidemiology,
characteristics,
outcomes
screening
controversies.
addition,
concepts
that
have
arisen
because
paradigm
such
MAFLD/NAFLD
non-overlapping
groups,
dual
aetiology
tumours
sub-phenotypes
reviewed.
Clinical and Molecular Hepatology,
Journal Year:
2022,
Volume and Issue:
29(Suppl), P. S17 - S31
Published: Nov. 29, 2022
“Metabolic
dysfunction-associated
fatty
liver
disease
(MAFLD)”
is
the
term
suggested
in
2020
to
refer
related
systemic
metabolic
dysregulation.
The
name
change
from
nonalcoholic
(NAFLD)
MAFLD
comes
with
a
simple
set
of
criteria
enable
easy
diagnosis
at
bedside
for
general
medical
community,
including
primary
care
physicians.
Since
introduction
term,
there
have
been
key
areas
which
superiority
over
traditional
NAFLD
terminology
has
demonstrated,
risk
and
extrahepatic
mortality,
associations,
identifying
high-risk
individuals.
Additionally,
adopted
by
number
leading
pan-national
national
societies
due
its
concise
diagnostic
criterion,
removal
requirement
exclude
concomitant
diseases,
reduction
stigma
associated
this
condition.
current
article
explores
differences
between
diagnosis,
benefit,
some
potential
limitations,
how
opened
up
new
fields
research.
Cardiovascular Diabetology,
Journal Year:
2022,
Volume and Issue:
21(1)
Published: Dec. 3, 2022
The
newly
proposed
term
"metabolic
dysfunction-associated
fatty
liver
disease"
(MAFLD)
is
replacing
the
old
"non-alcoholic
(NAFLD)
in
many
global
regions,
because
it
better
reflects
pathophysiology
and
cardiometabolic
implications
of
this
common
disease.
change
terminology
from
NAFLD
to
MAFLD
not
simply
a
single-letter
an
acronym,
since
defined
by
set
specific
positive
diagnostic
criteria.
In
particular,
definition
specifically
incorporates
within
classification
recognized
cardiovascular
risk
factors.
Although
convincing
evidence
supports
significant
association
between
both
MAFLD,
with
increased
CVD
morbidity
mortality,
neither
nor
have
received
sufficient
attention
Cardiology
community.
fact,
there
paucity
scientific
guidelines
focusing
on
burdensome
disease
professional
societies.
This
Perspective
article
discusses
rationale
clinical
relevance
for
Cardiologists
definition.
HepatoBiliary Surgery and Nutrition,
Journal Year:
2023,
Volume and Issue:
12(3), P. 386 - 403
Published: Feb. 24, 2023
With
the
rising
global
prevalence
of
fatty
liver
disease
related
to
metabolic
dysfunction,
association
this
common
condition
with
chronic
kidney
(CKD)
has
become
increasingly
evident.
In
2020,
more
inclusive
term
dysfunction-associated
(MAFLD)
was
proposed
replace
non-alcoholic
(NAFLD).
The
observed
between
MAFLD
and
CKD
our
understanding
that
can
be
a
consequence
underlying
dysfunction
support
notion
individuals
are
at
higher
risk
having
developing
compared
those
without
MAFLD.
However,
date,
there
is
no
appropriate
guidance
on
in
Furthermore,
been
little
attention
paid
link
Nephrology
community.Using
Delphi-based
approach,
multidisciplinary
panel
50
international
experts
from
26
countries
reached
consensus
some
open
research
questions
regarding
CKD.This
statement
provided
epidemiology,
mechanisms,
management
treatment
CKD,
as
well
relationship
severity
which
establish
framework
for
early
prevention
these
two
interconnected
diseases.
Gut,
Journal Year:
2023,
Volume and Issue:
72(7), P. 1399 - 1409
Published: Jan. 4, 2023
Objective
A
simple
combined
score
with
liver
stiffness,
controlled
attenuation
parameter
and
serum
aspartate
aminotransferase
(AST),
the
FibroScan-AST
(FAST)
score,
has
been
proposed
to
non-invasively
identify
patients
fibrotic
non-alcoholic
steatohepatitis
(NASH).
We
performed
a
systematic
review
meta-analysis
of
published
studies
evaluate
overall
diagnostic
accuracy
FAST
in
identifying
NASH.
Design
systematically
searched
MEDLINE,
Ovid
Embase,
Scopus
Cochrane
Library
electronic
databases
for
full-text
articles
any
language
between
3
February
2020
30
April
2022.
included
original
that
reported
data
calculation
sensitivity
specificity
adult
NASH
adults,
according
previously
described
rule-out
(≤0.35)
rule-in
(≥0.67)
cut-offs.
Results
12
observational
total
5835
participants
biopsy-confirmed
fatty
disease.
The
pooled
prevalence
was
28%
(95%
CI
21%
34%).
score’s
89%
82%
93%),
83%
94%)
aforementioned
rule-in/rule-out
negative
predictive
value
positive
were
92%
91%
95%)
65%
53%
68%),
respectively.
Subgroup
analyses
influential
bias
did
not
alter
these
findings.
Conclusion
results
our
show
good
performance
non-invasive
diagnosis
Therefore,
this
can
be
used
efficiently
who
should
referred
conclusive
biopsy
and/or
consideration
treatment
emerging
pharmacotherapies.
PROSPERO
registration
number
CRD42022350945.
